Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1845-1850

  Sun, Ji Min ^a   Wang, Chun Miao ^a   Guo, Zeng ^a   Hao, Yu Yu ^b   Xie, Yang Jing ^a   Gu, Jian ^b   Wang, Ai Ling ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b First Hefei People's Hospital   (China)

Author keywords

Hypertrophy; KATP channel agonist; Myocardial connexin43

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CONNEXIN 43; GLIBENCLAMIDE; ISOPRENALINE; NICORANDIL; SODIUM CHLORIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; IMMUNOCYTOCHEMISTRY; ISOPROTERENOL-INDUCED CARDIAC HYPERTROPHY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGONISTS; ANIMAL; BLOOD; CARDIOMEGALY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEART MUSCLE; HEART VENTRICLE; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY;

RATTUS;

ANIMALS; CARDIOMEGALY; CONNEXIN 43; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEART VENTRICLES; IMMUNOHISTOCHEMISTRY; ISOPROTERENOL; KATP CHANNELS; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NICORANDIL; RATS; RNA, MESSENGER;

EID: 84916618581     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2988     Document Type: Article

References (34)

1. Weber KT, Anversa P, Armstrong PW, et al: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20: 3-16, 1992.
2. Verdecchia P, Carini G, Circo A, et al; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38: 1829-1835, 2001.
3. Choudhary R, Mishra KP and Subramanyam C: Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant. Indian J Clin Biochem 21: 107-113, 2006.
4. Rajesh KG, Sasaguri S, Suzuki R, Xing Y and Maeda H: Ischemic preconditioning prevents reperfusion heart injury in cardiac hypertrophy by activation of mitochondrial KATP channels. Int J Cardiol 96: 41-49, 2004.
5. Lee TM, Lin MS and Chang NC: Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts. J Am Coll Cardio 51: 1309-1318, 2008.
6. Ennis IL, Escudero EM, Console GM, et al: Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition. Hypertension 41: 1324-1329, 2003.
7. Frohlich ED: State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 34: 782-789, 1999.
8. Joyner RW: Effects of the discrete pattern of electrical coupling on propagation through an electrical syncytium. Circ Res 50: 192-200, 1982.
9. Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI and Gutstein DE: Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res 95: 1035-1041, 2004.
10. Boengler K, Dodoni G, Rodriguez-Sinovas A, et al: Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 67: 234-244, 2005.
11. Roell W, Lewalter T, Sasse P, et al: Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450: 819-824, 2007.
12. Rottlaender D, Boengler K, Wolny M, et al: Connexin 43 acts as a cytoprotective mediator of signal transduction by stimulating mitochondrial KATP channels in mouse cardiomyocytes. J Clin Invest 120: 1441-1453, 2010.
13. Wang A, Chen F, Xie Y, Guo Z and Yu Y: Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown) 13: 511-515, 2012.
14. de Lemos JA, McGuire DK and Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 362: 316-322, 2003.
15. Tang Y, Wang M, Le X, et al: Antioxidant and cardioprotective effects of Danshensu (3-(3,4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats. Phytomedicine 18: 1024-1030, 2011.
16. Pfeffer MA and Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172, 1990.
17. Sakai K: Nicorandil: animal pharmacology. Am J Cardiol 63: 2J-10J, 1989.
18. Lee TM, Lin CC, Lien HY and Chen CC: K ATP channel agonists preserve connexin43 protein in infarcted rats by a protein kinase C-dependent pathway. J Cell Mol Med 16: 776-788, 2012.
19. Guéant Rodriguez RM, Spada R, Pooya S, et al: Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol 167: 768-775, 2013.
20. Swedberg K, Cleland J, Dargie H, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26: 1115-1140, 2005.
21. Kimura T, Kitamura H, Inoue K, et al: Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease. Clin Exp Nephrol 15: 854-860, 2011.
22. Kanno S and Saffitz JE: The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 10: 169-177, 2001.
23. Egashira K, Nishii K, Nakamura K, Kumai M, Morimoto S and Shibata Y: Conduction abnormality in gap junction protein connexin45-deficient embryonic stem cell-derived cardiac myocytes. Anat Rec A Discov Mol Cell Evol Biol 280: 973-979, 2004.
24. Wang Y and Hill JA: Electrophysiological remodeling in heart failure. J Mol Cell Cardiol 48: 619-632, 2010.
25. Ohara T, Ohara K, Cao JM, et al: Increased wave break during ventricular fibrillation in the epicardial border zone of hearts with healed myocardial infarction. Circulation 103: 1465-1472, 2001.
26. Naitoh K, Ichikawa Y, Miura T, et al: MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res 70: 374-383, 2006.
27. Amino M, Yoshioka K, Tanabe T, et al: Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction. Cardiovasc Res 72: 412-421, 2006.
28. Döring G: Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 20 (Suppl 3): S74-S81, 1992.
29. The SWAN Study Group: Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 2: 213-217, 1999.
30. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O and de Divitiis M: A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 7: 119-123, 1993.
31. Zhu WL, Shan YD, Guo JX, et al: Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 71: 826-833, 2007.
32. Baines CP, Liu GS, Birincioglu M, Critz SD, Cohen MV and Downey JM: Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol 276: H1361-H1368, 1999.
33. Sugimoto K, Ito H, Iwakura K, et al: Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 67: 295-300, 2003.
34. Garlid KD, Paucek P, Yarov-Yarovoy V, et al: Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 81: 1072-1082, 1997.